Clinical data
Routes of
Synonyms RAD-1901, ER-306323
CAS Number 722533-56-4
PubChem (CID) 23642301
ChemSpider 57583807
Chemical and physical data
Formula C30H38N2O2
Molar mass 458.63492 g/mol
3D model (Jmol) Interactive image

Elacestrant (INN) (developmental code names RAD-1901, ER-306323) is a non-steroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) (described as a "SERM/SERD hybrid (SSH)") that was discovered by Eisai and is under development by Radius Health and Takeda for the treatment of menopausal vasomotor symptoms (hot flashes) and estrogen receptor (ER)-positive advanced breast cancer, as well as endometrial cancer and kidney cancer.[1][2][3][4][5] As of September 2016, it is in phase II clinical trials for vasomotor symptoms and breast cancer.[2][5] Elavestrant has dose-dependent, tissue-selective estrogenic and antiestrogenic activities, with biphasic weak partial agonist activity at the ER at low doses and antagonist activity at higher doses.[3] It shows agonistic activity on bone and antagonistic activity on breast and uterine tissues.[4] Unlike the SERD fulvestrant, elacestrant is able to readily cross the blood-brain-barrier into the central nervous system, where it can target breast cancer metastases in the brain,[3][4] and is orally bioavailable and does not require intramuscular injection.[3][4]

See also


This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.